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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food
Allergens (NDA) was asked to deliver an opinion on viable embryonated eggs of the whipworm Trichuris
suis as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The applicant proposes to use the NF
as a food supplement in the format of a 15-mL bottle containing 250 viable embryonated eggs of T. suis.
The target population for the NF is the general population. Considering the compositional data and
proposed conditions of use, the consumption of the NF is considered of no nutritional relevance. Available
data suggest that most larvae of T. suis after hatching in the intestinal tract of humans remain immature
and live for several weeks in the gastrointestinal tract of the human host. Nevertheless, under certain
circumstances, T. suis can be invasive in human, being able to mature into adult size and reproduce in
humans. Human studies have also shown that administration of T. suis ova may increase the incidence of
adverse gastrointestinal reactions. The Panel considers that there are no studies available that
demonstrate the safety of this NF intended for the general population at a proposed intake of 250 viable
embryonated eggs of T. suis ova per day. Based on the available information, the Panel cannot establish
a safe dose at which no safety concerns would be expected. The Panel concludes that the safety of the
NF has not been established.
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Summary
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on viable embryonated eggs of the whipworm
Trichuris suis as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The assessment of the
safety of this NF, which follows the methodology set out in the EFSA Guidance on the preparation and
presentation of an application for authorisation of a NF1 in the context of Regulation (EU) 2015/2283
and in the Commission Implementing Regulation (EU) 2017/2469, is based on the data supplied in the
application, information submitted by the applicant following EFSA’s requests for supplementary
information and additional information identified by the Panel.
The NF which is the subject of the application are embryonated eggs of the whipworm T. suis. The
NF is intended to be marketed as a food supplement in the format of a 15-mL bottle containing 250
viable embryonated eggs of T. suis. The target population for the NF is the general population.
Considering the compositional data and proposed conditions of use, the consumption of the NF is
considered of no nutritional relevance. Available data suggest that most larvae of T. suis after hatching
in the intestinal tract of humans remain immature and live for several weeks in the gastrointestinal
tract of the human host. Nevertheless, under certain circumstances, T. suis can be invasive in human,
being able to mature into adult size and reproduce in humans. Human studies have also shown that
administration of T. suis ova may increase the incidence of adverse gastrointestinal reactions.
The Panel considers that there are no studies available that demonstrate the safety of this NF
intended for the general population at a proposed intake of 250 viable embryonated eggs of T. suis
ova per day. Based on the available information, the Panel cannot establish a safe dose at which no
safety concerns would be expected. The Panel concludes that the safety of the NF has not been
established.
1 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G, Pentieva
K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M, Salminen S,
Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on the preparation
and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal
2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
Safety of viable embryonated eggs of the whipworm T. suis as a novel food
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2019;17(8):5777
Table of contents
Abstract................................................................................................................................................... 1
Summary................................................................................................................................................. 3
1. Introduction................................................................................................................................ 5
1.1. Background and Terms of Reference as provided by the European Commission ............................... 5
2. Data and methodologies .............................................................................................................. 5
2.1. Data........................................................................................................................................... 5
2.2. Methodologies............................................................................................................................. 5
3. Assessment................................................................................................................................. 5
3.1. Introduction................................................................................................................................ 5
3.2. Identity of the NF........................................................................................................................ 5
3.3. Production process ...................................................................................................................... 6
3.4. Compositional data...................................................................................................................... 6
3.4.1. Stability ...................................................................................................................................... 7
3.5. Specifications .............................................................................................................................. 7
3.6. History of use of the NF and/or of its source ................................................................................. 7
3.7. Proposed uses and use levels and anticipated intake...................................................................... 7
3.7.1. Target population ........................................................................................................................ 7
3.7.2. Proposed uses and use levels ....................................................................................................... 8
3.7.3. Anticipated intake of the NF......................................................................................................... 8
3.8. Nutritional information ................................................................................................................. 8
3.9. Safety data ................................................................................................................................. 8
3.9.1. Pathogenicity/invasiveness information.......................................................................................... 8
3.9.2. Toxicological information.............................................................................................................. 8
3.9.2.1. Animal data ................................................................................................................................ 8
3.9.2.2. Human data................................................................................................................................ 9
3.9.3. Allergenicity ................................................................................................................................ 10
4. Discussion .................................................................................................................................. 10
5. Conclusions................................................................................................................................. 11
Steps taken by EFSA ................................................................................................................................ 11
References............................................................................................................................................... 11
Abbreviations ........................................................................................................................................... 12
Safety of viable embryonated eggs of the whipworm T. suis as a novel food
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2019;17(8):5777
1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 20 July 2018, the company Enteron Science GmbH submitted a request to the European
Commission in accordance with Article 10 of Regulation (EU) 2015/22832 to place viable embryonated
eggs of the whipworms (Trichuris suis) on the Union market as a novel food.
In accordance with Article 10 (3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on viable embryonated eggs of
whipworm (Trichuris suis) as a novel food.
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following an EFSA request for supplementary information.
During the assessment, the Panel identified additional data which were not included in the
application.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/2469.3
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.1 As indicated in this guidance, it is
the duty of the applicant to provide all the available (proprietary, confidential and published) scientific
data, including both data in favour and not in favour to supporting the safety of the proposed NF.
This NF application does not include a request for protection of proprietary data in accordance with
Article 26 of Regulation (EU) 2015/2283.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under
the proposed conditions of use and is not an assessment of the efficacy of viable embryonated eggs of
the whipworm Trichuris suis with regard to any claimed benefit.
3. Assessment
3.1. Introduction
The NF which is the subject of the application falls under the category ‘food consisting of, isolated
from or produced from animals or their parts’, as described in Article 3 of Regulation (EU) 2015/2283.
This NF is produced by Enteron Science GmbH and consist of viable embryonated eggs of the porcine
whipworm T. suis. The target population is the general population.
3.2. Identity of the NF
The NF assessed in this application is a non-sterile suspension of the viable embryonated eggs of
the whipworm T. suis. The whipworm T. suis is a nematode commonly present in the caecum and
colon of pigs. Adult worm size ranges from 3 to 8 cm with female being larger than male.
2 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/2011
of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the
Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22).
3 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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The intended format of the NF is: 250 viable embryonated eggs of T. suis suspended in 15 mL of
phosphate-buffered solution (pH 2.4) with potassium sorbate as an antimicrobial preservative. Eggs of
T. suis are oval, of microscopic size (60 9 25 lm), brownish and lemon-shaped with noticeable
protruding polar caps at both ends.
The identification of the source organism is performed by reverse transcription polymerase chain
reaction (RT-PCR) and is based on a specific sequence region of the ribosomal DNA. The identification
method is highly specific for T. suis with no relevant homology to other Trichuris species or other
common parasites in pigs such as Ascaris suum, Oesophagostomum dentatum and Hyostrongylus
rubidus.
3.3. Production process
The T. suis eggs are produced in minipigs (females, 80–150 days old, of approximately 6–13 kg
body weight). Minipigs are inoculated with 2,000 active T. suis eggs and following incubation for 49
days, faeces are collected until day 57 post-inoculation. Faeces are then pooled into three fractions
(those from days 49 to 51, those from days 52 to 54 and those from days 55 to 57).
Subsequently, eggs are isolated and purified from the faecal pools producing three individual egg
suspensions. For each suspension, the egg count is determined, and the yield is calculated. Portions of
eggs are taken from each suspension and pooled into one final bulk containing a total of 8 to 19
million eggs. Afterwards, eggs are matured in vitro (25°C, 90 days with 0.1 N sulfuric acid at pH 1) to
produce viable embryonated eggs. The first 30 days are considered as the inactivation step for viruses
by the applicant. Eggs are transferred into a phosphate buffer containing potassium sorbate as
preservative. Each batch originates from a group of 2–5 minipigs with an established T. suis infection
and its traceability is assured.
Finally, suspensions of viable embryonated eggs containing 250 eggs per bottle in 15 mL solution
are produced.
The NF is controlled/analysed regarding viral, microbial and parasite contamination. Information on
these aspects was provided by the applicant.
3.4. Compositional data
This NF consists of T. suis eggs in a phosphate-buffered solution preserved with potassium sorbate.
Compositional data were provided by the applicant (Table 1). The shell of the eggs consists of chitin.
Table 1: Composition
Parameter Result
Protein < 0.1 g/100 mL
Fat 0.1 g/100 mL
Dry matter 1.7 g/100 mL
Water 99.1 g/100 mL
Ash (minerals) 0.9 g/100 mL
Fibres < 0.02 g/100 mL
Carbohydrates 0.7 g
Energy value 16 kJ/4 kcal per 100 mL
D-Glucose < 0.1 g/100 g
D-Fructose < 0.1 g/100 g
Sucrose < 0.1 g/100 g
Maltose < 0.1 g/100 g
Lactose < 0.1 g/100 g
Total sugars < 0.1 g/100 g
Salt 0.9 g/100 g
Sodium 370.6 mg/100 g
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3.4.1. Stability
The shelf life established by the applicant is linked to the viability of the embryonated eggs. The
compositional characteristics of the suspension medium remain stable for at least 12 months when
stored at 2–8°C. Under these conditions, the applicant claims that sufficient activity and viability of
T. suis can be maintained for at least 12 months. The applicant proposes a shelf life of 15 months
when stored at 2–8°C.
3.5. Specifications
The applicant assessed potential contaminants of the NF, unwanted accompanying substances,
microorganisms, pathogenic viruses and other helminth eggs. According to the applicant, unwanted
accompanying substances are removed during the purification step (see Section 3.3). Specifications of
the NF proposed by the applicant are indicated in Table 2.
3.6. History of use of the NF and/or of its source
The applicant states that humans have been exposed to T. suis eggs from pigs since centuries, in
particular farm workers. The applicant states that this NF is commercialised in Thailand.
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population proposed by the applicant is the general population.
Table 2: Specifications of the NF
Parameter Specifications Method of analysis
Appearance of
solution
Clear solution. A slight sediment might be visible on
standing which disappears completely after shaking
Visual examination
Identity of
Trichuris species,
embryonated
Positive for Trichuris species, embryonated (lemon-
shaped eggs with a thick shell and transparent
protruding polar caps containing a folded larva)
Microscopic determination of
morphological characteristics
Identity of
Trichuris suis
species,
embryonated
Positive amplification of the Trichuris suis ITS2
sequence
RT-PCR of the Trichuris suis ITS2
sequence
Potassium sorbate ≥ 0.40 mg/mL equivalent to ≥ 80% of the labelled
amount
HPLC
TSO(a) inactive
(embryonated and
non-embryonated)
< 20% (motility index in relation to TSOtotal) Microscopic determination
Assay TSOtotal
• TSO 250
120–495 TSOtotal/bottle (8–33 TSOtotal/mL)
corresponding to 120–390 TSOactive/bottle
Microscopic counting
Potency in vitro
(TSO active)
• Motility index
• ATP assay
≥ 80 % of the eggs contain motile/active larva
≥ 25 nM of ATP is induced by 1,260 (1,120–1,400)
eggs (after thermal stimulation)
Microscopic determination
Luciferase reaction
Microbiological
quality
Total aerobic microbial count ≤ 104 CFU/mL
Total yeast and mould count ≤ 102 CFU/mL
E. coli Absent (1 mL)
Enterobacteria and certain other
Gram-negative bacteria ≤ 102 CFU/mL
Salmonella Absent (10 mL)
Staphylococcus aureus Absent (1 mL)
According to requirements of the
pour-plate method and of the
test for specific microorganisms
ITS2: internal transcribed spacer 2; RT-PCR: Reverse transcription polymerase chain reaction; HPLC: high-performance liquid
chromatography; ATP: adenosine triphosphate; CFU: colony forming units.
(a): Trichuris suis ova.
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3.7.2. Proposed uses and use levels
The applicant intends to market the NF for use as a food supplement in the format of 15 mL
bottles containing 250 viable embryonated eggs of T. suis.
3.7.3. Anticipated intake of the NF
The applicant proposes an intake of one 15-mL bottle with 250 viable embryonated eggs of T. suis
per day.
3.8. Nutritional information
Considering the compositional data and proposed conditions of use, the consumption of the NF is
considered of no nutritional relevance.
3.9. Safety data
Trichuris suis is a host-specific porcine enteropathogenic parasite in the caecum and colon of
affected pigs (Batte et al., 1977).
Potential concerns associated to this NF are related to two aspects: (i) invasiveness/infestation of
human by T. suis; and (ii) immunological reactions to excretory/secretory peptides. Regarding the
immunological reactions, it is known that hatched larvae excrete a group of peptides called excretory/
secretory antigens with the aim to survive and persist in the host. These peptides interact with the immune
system of the host provoking measurable reactions of the immune system (described further below).
3.9.1. Pathogenicity/invasiveness information
The first studies of potential infections to T. suis in human date back to the 1970s. It was reported
that T. suis larvae are able to transiently colonise humans after administration of single oral doses
(1,000 or 5,000 T. suis ova) but were eliminated after several weeks of the inoculation. Moreover, no
adverse effects were reported (Beer, 1971, 1976). However, a case of invasiveness of T. suis in the
human host was showed by Kradin et al. (2006) after administration of T. suis ova (5 oral doses of
2,500 ova) in a 16-year-old individual with Crohn’s disease. The authors reported an iatrogenic T. suis
infection, characterised by a lymphoplasmatic infiltrate with a substantial number of eosinophil counts
consistent with the development of a T helper 2 (Th2)-mediated response, and raised the concern of
persistent active infection in humans. Williams et al. (2017) investigated the pathogenicity and immune
response developed following the administration of T. suis in a healthy volunteer. The authors reported
that T. suis is able to colonise the human colon, to mature to adult size and to reproduce in humans.
Furthermore, genetic analysis of whipworms obtained from the faeces of 12 schoolchildren in Uganda
identified one isolate as T. suis and two other isolates which showed genetic characteristics of the
porcine and human whipworm (Nissen et al., 2012). Finally, infection of humans with T. suis has
recently been studied in populations in Thailand by molecular techniques where T. suis was identified
in one out of 27 faecal samples analysed. The authors raised awareness of a zoonotic potential of
T. suis in Thailand (Phosuk et al., 2018).
Beer (1973) indicated that T. suis might provoke epithelial damage favouring other secondary
pathogenic infections in piglets. A life-threatening Campylobacter jejuni colitis, associated with
concomitant human whipworm ova in faeces, was reported in a human case report (Shin et al., 2004).
These authors suggested that excretory/secretory products (e.g. proteases and glycoproteins) of
whipworms could induce epithelial damage promoting Campylobacter attachment.
While Hsu et al. (2005) also raised concerns about the fate of T. suis ova; they proposed to provide
anti-helminth agents after completion of trials with T. suis. According to information provided by the
applicant, attention should be directed to an increased risk of microbial or other superinfection in
patients treated with T. suis. Also, the applicant argued that if symptoms should occur, the causative
agent could be treated with anti-helminthic drugs.
3.9.2. Toxicological information
3.9.2.1. Animal data
The main animal studies presented by the applicant were: single dose toxicity studies in monkeys
and rabbits (up to 25,000 T. suis ova/kg body weight (bw) in monkey and up to 33,000 T. suis ova/kg
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bw in rabbits); subchronic repeated dose toxicity studies in monkeys (a 7-week study using two
animals per gender per group administered once weekly placebo, 500 T. suis ova/kg bw or 1,000
T. suis ova/kg bw; and a 13-week study using six animals per gender per group administered every
two weeks placebo, 500 T. suis ova/kg bw or 2,500 T. suis ova/kg bw); and a reproductive/
developmental toxicity study in rabbits (24 animals per group and gender administered every two
weeks during pre-mating and the mating period doses of 500, 2,500 and 7,500 T. suis ova/animal
while, during gestation, females were dosed weekly).
The applicant considered that rabbits and monkeys were relevant models for toxicity studies in this
application. This is because they are non-natural hosts susceptible to a transient colonisation. Rats
were identified as not susceptible to infection. The monkey is considered the most relevant model for
T. suis for the safety assessment in human, while rabbit was mainly selected for the reproductive/
developmental toxicity studies.
The main findings reported by the applicant were transient colonisation restricted to the mucosa of
the caecum and colon in treatment groups of rabbits and monkeys where focal alterations were
occasionally observed. No migration of T. suis into other tissues was described by the applicant. The
host reaction was dominated by an increase in eosinophils in blood and infiltration of eosinophils in the
mucosa of caecum and colon. The applicant referred to the formation of specific immunoglobulin G
(IgG) antibodies against T. suis and an increased expression of Th2 cytokines in activated mononuclear
cells of the peripheral blood and intestinal tissue. No diarrhoea or blood in stool was reported. In the
subchronic study in monkeys, the applicant also reported that ‘in the male animals of the high dose
group on day 40 of treatment showed a tendency to softened faeces was noted’. In relation to the
reproductive/developmental studies, the applicant reported that administration of T. suis ova provoked
no effect on fertility and embryo-fetal development and it showed no teratogenic properties.
EFSA requested full study reports of the 13-week repeated dose toxicity study in monkeys and of
the reproductive/developmental toxicity study in rabbits, but these were not made available to EFSA.
In addition, the Panel considered other animal studies available in the literature. Leonardi et al.
(2017) investigated the safety of T. suis in an immunocompetent and immunosuppressed host (using a
rabbit model of dextran sodium sulfate-induced colitis). The authors showed that T. suis aggravate
colitis in immunocompromised groups of rabbits receiving cyclosporine and methylprednisolone.
Other studies investigating the immunomodulatory effects of the excretory/secretory products of
T. suis were referred to by the applicant or identified by EFSA (Parthasarathya and Mansfield, 2005;
Ebner et al., 2014; Hansen et al., 2017; Laan et al., 2017; Leroux et al., 2018). The evidence available
suggests an interaction between T. suis and the hosts’ immune systems towards the promotion of a
modified Th2 immune response. These studies were oriented at studying modulation of immune
responses. The Panel notes that these studies were not designed to assess potential adverse
consequences of exposure to the excretory/secretory products of T. suis.
3.9.2.2. Human data
Information on clinical trials in the original dossier mainly focused on the efficacy of the T. suis ova.
These studies included trials involving individuals suffering from inflammatory bowel disease (Summers
et al., 2003, 2005a,b; Elliott et al., 2005), multiple sclerosis (Flemming et al., 2009) and allergic rhinitis
(Bager et al., 2010). No clinical trials have been performed in healthy individuals including children.
In addition to the studies referred to by the applicant, the Panel identified a number of additional
studies in the literature that are also described below.
Bager et al. (2010) performed a randomised, double-blind, placebo-controlled clinical trial in 100
individuals with allergic rhinitis allocated to ingest either 8 doses with 2500 live T. suis ova or placebo
(a dose every 3 weeks). The authors reported a transient diarrhoea peaking at day 41 in 33% of the
group treated with T. suis compared to the 2% in the placebo group. Upper abdominal pain in the
T. suis group was 37% vs 4% in placebo and flatulence 43% vs 17% being significantly more frequent
in the T. suis ova group. According to the authors, superficial damage to the intestinal mucosa by
T. suis larvae after hatching could be the reason of such clinical observation. An immunologic response
due to the infection, i.e. increased eosinophil counts and increased immunoglobulin E (IgE), IgG, IgG4
and immunoglobulin A (IgA) against T. suis, was also observed. The authors concluded that the
treatment with T. suis induced a clinical and immunological response and a high prevalence of adverse
gastrointestinal reactions. In 2011, Bager et al. described in detail the data on the adverse events and
the analyses of the gastrointestinal reactions. The authors concluded that the repeated ingestions
caused reactions lasting for two weeks. In addition, four months of treatment with T. suis provoked a
3- to 19-fold increased rate of incidents with flatulence, diarrhoea and abdominal pain.
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The potential use of helminths for the treatment of inflammatory bowel disease (e.g. ulcerative colitis,
Crohn’s disease) was investigated by Summers et al. (2003). In this open trial study, seven individuals
with either ulcerative colitis or Crohn’s disease were administered a single dose of 2,500 T. suis ova and
followed biweekly for 12 weeks. In the same study, four individuals received 2,500 ova every 3 weeks
following the same evaluation scheme. No adverse effects were reported. In an additional study, 29
individuals with active Crohn’s disease ingested 2,500 T. suis ova every 3 weeks for 24 weeks and this was
considered as safe for subjects suffering from Crohn’s disease by the authors (Summers et al., 2005a).
Subsequently, a randomised, double-blind, placebo-controlled trial with 54 individuals suffering from
active colitis were given 2,500 T. suis ova or placebo biweekly for 12 weeks. The treatment was reported
not to induce side effects (Summers et al., 2005b). The authors stated that adverse events are likely to be
rare, and if symptoms would occur, the agent can be easily treated with a readily available anthelminthic.
This study also included a crossover phase where individuals on placebo were switched to T. suis and
those on T. suis to placebo for another 12 weeks with no adverse effects observed (Elliott et al., 2005).
Sandborn et al. (2013) considered the safety of T. suis ova in 36 individuals suffering from Crohn’s disease
and receiving a single dose of the helminths and no relevant side effects were reported. The authors of
this study highlighted the challenge of this type of studies with embryonated T. suis eggs in individuals
suffering from an inflammatory bowel disease, and whether to assign gastrointestinal symptoms to the
treatment with T. suis or to the underlying disease. Sch€olmerich et al. (2017) reported that dosing 250,
2,500 and 7,500 of T. suis ova biweekly over 12 weeks did not provoke adverse effects. Similarly to other
studies (Bager et al., 2010, 2011; Flemming et al., 2011), Schoelmerich and collaborators suggested that
adverse effects are not likely to be observed in this type of studies because of an overlap of effects of
T. suis with symptoms related to the underlying disease in the individuals tested.
Flemming et al. (2011) reported gastrointestinal side effects following T. suis ova treatment. Three
of the five individuals suffering from multiple sclerosis treated with T. suis reported mild intestinal
symptoms. Similar experiments were performed by Benzel et al. (2012) where four individuals were
administered 2,500 T. suis ova biweekly during 6 months for the treatment of multiple sclerosis. The
authors reported that the treatment was well tolerated with no side-effect except for mild
gastrointestinal symptoms in one patient likely related to the T. suis treatment. Furthermore,
Voldsgaard et al. (2015) evaluated the safety and efficacy of 2,500 T. suis ova administered biweekly
for 12 weeks to 10 individuals with multiple sclerosis. The treatment was well-tolerated with mild and
self-limiting gastrointestinal symptoms.
The Panel considers that the uncontrolled studies enrolling small numbers of subjects are not
suitable for the assessment of this NF (Flemming et al., 2011; Benzel et al., 2012; Voldsgaard et al.,
2015). The Panel also notes that studies with patients suffering from inflammatory bowel disease
(Summers et al., 2003, 2005a,b; Elliott et al., 2005) have inherent limitations for their use in the safety
assessment of a viable intestinal parasite.
3.9.3. Allergenicity
Bager et al. (2010) noted specific IgE production in humans exposed to 8 doses of 2,500 viable
T. suis eggs in a human study. No other studies addressing potential adverse effects linked to the
allergen capacity of the NF were provided by the applicant. In addition, no studies on cross-reactivity
between T. suis and known allergens were identified.
4. Discussion
Several studies have investigated the immunomodulatory capacity of the excretory/secretory
proteins of T. suis to modulate their host’s immune system in order to survive and persist. Available
data suggest that most larvae of T. suis after hatching remain immature and live for several weeks in
the gastrointestinal tract of the human host, but they occasionally can develop into adult worms. Case
reports in the literature showed that under certain circumstances, T. suis is invasive in humans and can
mature to adult size and reproduce in humans. The potential infection of humans with T. suis has been
confirmed in populations in Uganda and Thailand.
Available human studies mainly investigated potential effects of viable T. suis in individuals suffering
from allergic rhinitis, inflammatory bowel disease or multiple sclerosis. Several of these studies were
uncontrolled and enrolled only a low number of subjects. The Panel also considers that studies with
patients suffering from inflammatory bowel disease have inherent limitations mainly because of an
overlap of effects of T. suis with symptoms related to the disease in the individuals tested and are not
suitable to demonstrate the safety of this NF.
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One randomised, double-blind, placebo-controlled clinical trial in 100 individuals with allergic rhinitis
and receiving 8 doses of 2,500 embryonated T. suis eggs (a dose every 3 weeks) or placebo reported
a significantly increased incidence of diarrhoea, abdominal pain and flatulence in the T. suis group
versus the placebo group. Repeated intake of embryonated T. suis eggs caused reactions lasting for
two weeks. In addition, the authors reported that four months of treatment with T. suis caused in
total, a 3- to 19-fold increased rate of episodes with flatulence, diarrhoea and abdominal pain.
The Panel notes that the intake proposed by the applicant is 250 viable embryonated eggs of
T. suis ova per day, i.e. lower levels than those at which gastrointestinal effects in that randomised
controlled trial were observed. However, the Panel considers that there are no data available which
would allow to conclude that the reported gastrointestinal effects when dosing 2,500 eggs would not
occur at the proposed intake of 250 eggs per day.
5. Conclusions
The Panel concludes that the safety of the NF has not been established.
Steps taken by EFSA
1) Letter from the European Commission to EFSA with the request for a scientific opinion on the
safety of viable embryonated eggs of the whipworm (Trichuris suis) as a novel food. Ref.
Ares(2018)5333065, dated 17 October 2018.
2) On 17 October 2018, EFSA received a valid application from the European Commission on
viable embryonated eggs of the whipworm (Trichuris suis) as a novel food, which was
submitted by the company Enteron Science GmbH, and the scientific evaluation procedure
started.
3) On 5 March 2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
4) On 6 May 2019, additional information was provided by the applicant and the scientific
evaluation was restarted.
5) During its meeting on 2 July 2019, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of viable embryonated eggs of the whipworm (Trichuris suis)
as a novel food pursuant to Regulation (EU) 2015/2283.
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Abbreviations
ATP adenosine triphosphate
bw body weight
CFU colony forming units
HPLC high-performance liquid chromatography
IgA immunoglobulin A
IgE immunoglobulin E
IgG immunoglobulin G
ITS2 internal transcribed spacer 2
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LOD limit of detection
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
NF Novel Food
RT-PCR reverse transcription polymerase chain reaction
Th T helper
TSO Trichuris suis ova
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